Lars Fruergaard Jørgensen, Novo Nordisk CEO (Christopher Goodney/Bloomberg via Getty Images)
August 10, 2023 07:32 AM EDTUpdated 11:19 AM
Pharma

No­vo Nordisk boasts $14.6B in H1 obe­si­ty, di­a­betes sales, but ques­tions linger on broad­er cov­er­age

Katherine Lewin

News Reporter

No­vo Nordisk’s sales from its obe­si­ty and di­a­betes care prod­ucts in­creased by 36% to $14.6 bil­lion (99 bil­lion Dan­ish kro­ner) in the first half of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er ends work on Sang­amo's he­mo­phil­ia gene ther­a­py, crush­ing biotech's hopes

Flag­ship biotech Va­lo Health ends 2024 with mid-stage fail

No­var­tis ends Phase 1 ra­dio­phar­ma tri­al; Solve Ther­a­peu­tics pur­sues $75M round

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

A service from the Financial Times